Cytosorbents Corp - SIC # 3845 - ELECTROMEDICAL AND ELECTROTHERAPEUTIC APPARATUS

Ticker Exchange SIC # Website Latest Ticker
CTSO Nasdaq 3845 http://cytosorbents.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cytosorbents Corp

CytoSorbents to Present at Two Upcoming Investor Conferences - May 19th, 2022 11:00 am
Cytosorbents Corporation (NASDAQ:CTSO): When Will It Breakeven? - May 12th, 2022 3:58 pm
CytoSorbents Reports First Quarter 2022 Results and Revises 2022 Outlook - May 3rd, 2022 8:15 pm
CytoSorbents Awarded Preferred Supplier Agreement with Asklepios, One of the Largest Private Hospital Operators in Germany - May 2nd, 2022 11:00 am
First Patient Enrolled in U.S. STAR-D Pivotal Trial Evaluating the DrugSorb™-ATR Antithrombotic Removal System to Remove Apixaban and Rivaroxaban During Cardiothoracic Surgery - Apr 29th, 2022 11:00 am
CytoSorbents Highlights the Strategy of "Enhanced Lung Rest" Using CytoSorb with ECMO to Help Treat Lung Failure at the 10th EuroELSO Congress - Apr 28th, 2022 11:00 am
CytoSorbents to Report First Quarter 2022 Operating and Financial Results - Apr 19th, 2022 11:00 am
CytoSorbents To Expand Direct Sales of CytoSorb® to the United Kingdom, the Sixth Largest Medical Device Market in the World - Apr 14th, 2022 11:00 am
Cytosorbents (NASDAQ:CTSO) investors are sitting on a loss of 67% if they invested a year ago - Apr 12th, 2022 3:21 pm
CytoSorbents Receives Approximately $740,000 from the New Jersey Business Tax Certificate Transfer Program - Apr 7th, 2022 11:00 am
CytoSorbents Appoints Jiny Kim, MBA to its Board of Directors - Apr 5th, 2022 11:00 am
CytoSorbents Highlights Activities at the Live 41st International Symposium on Intensive Care and Emergency Medicine (ISICEM) - Mar 17th, 2022 11:00 am
CytoSorbents Reports Fourth Quarter and Full Year 2021 Results and Provides 2022 Outlook - Mar 8th, 2022 9:15 pm
We're Hopeful That Cytosorbents (NASDAQ:CTSO) Will Use Its Cash Wisely - Feb 26th, 2022 12:09 pm
CytoSorbents to Report Fourth Quarter and Full Year 2021 Operating and Financial Results - Feb 8th, 2022 12:00 pm
CytoSorbents Announces Participation in Two Upcoming Virtual Investor Conferences - Feb 3rd, 2022 12:00 pm
First Patient Enrolled in the PROCYSS Multicenter Randomized Controlled Trial Evaluating CytoSorb® to Restore Hemodynamic Stability in Patients with Refractory Septic Shock - Feb 1st, 2022 12:00 pm
New Publication Reports Significant Reductions in Perioperative Bleeding Complications Following Acute Aortic Dissection Surgery using CytoSorbents' Antithrombotic Drug Removal Technology - Jan 24th, 2022 12:00 pm
CytoSorbents Expects Upside FY21 Sales, Despite COVID-19 Headwinds - Jan 18th, 2022 3:57 pm
CytoSorbents Issues Stockholder Letter and Reports Preliminary Fourth Quarter and Full Year 2021 Revenue - Jan 18th, 2022 12:00 pm